SCHEMBL16901686

SCHEMBL16901686

C1=Cc2occc2CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3630447 0.62
SCHEMBL15914282 0.61 GSK3A (0.42)
SCHEMBL6289130 0.61
SCHEMBL3630449 0.61
SCHEMBL8803337 0.59
SCHEMBL13677131 0.58
SCHEMBL18290453 0.58
SCHEMBL4138035 0.58
Bromide SCHEMBL19031040 0.58 PARP1 (0.91)
Iodide SCHEMBL7226882 0.58 PARP1 (0.91)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022143740-A1 ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND USE THEREOF 浙江春禾医药科技有限公司 2022-07-07 WO disclosed
EP-2920176-B1 AMINOIMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS Bayer Pharma AG (DE) 2017-09-13 EP disclosed
EP-2714692-B1 SUBSTITUTED AMINOIMIDAZOPYRIDAZINES BAYER IP GMBH (DE) 2017-03-22 EP disclosed
WO-2015104254-A1 AMIDO-SUBSTITUTED IMIDAZOPYRIDAZINES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE AND/OR ANGIOGENESIS DISORDERS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-07-16 WO disclosed